Cardiovascular side effects of novel antipsychotics

CNS Spectrums

Volumn 6, Issue 11, 2001, Pages 912-918

  Gupta, Sanjay ^a   Masand, Prakash S ^a   Kothari, Ashok J ^a  

^a Olean General Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; DROPERIDOL; HALOPERIDOL; MESORIDAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; ZIPRASIDONE;

AGED; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; DOSE RESPONSE; DRUG CLEARANCE; DRUG OVERDOSE; ELECTROCARDIOGRAPHY; FEMALE; HUMAN; METABOLIC INHIBITION; ORTHOSTATIC HYPERTENSION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; QT INTERVAL; REVIEW; RISK FACTOR; TORSADE DES POINTES;

EID: 0035715252     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900000973     Document Type: Review

References (68)

1. Antipsychotic drugs and cardiovascular safety: Current studies of prolonged QT interval and risk of ventricular arrhythmia
2. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients
3. Measurement of QT interval and the risk associated with QTc interval prolongation: A review
4. Cardiac effects of antipsychotics medications
5. Drug-induced torsades de pointes: Incidence management and prevention
6. Antipsychotic agents and QT changes
7. Quinidine syncope: Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias
8. Incidence and clinical features of quinidine associated long QT syndrome: Implications for patient care
9. Torsades de pointes: The long-short initiating sequence and other clinical features: Observations in 32 patients
10. Torsades de pointes due to quinidine: Observations in 31 patients
11. The Danish investigation of arrhythmia and mortality on dofetilide study group: Dofetilide in patients with congestive heart failure and left ventricular dysfunction
12. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter to fibrillation
13. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications
14. Safety concerns over antipsychotic drug sertindole
15. Clozapine
16. General pharmacology of clozapine
17. Clozapine: Guidelines for clinical management
18. Clinical profile of clozapine; adverse reactions and agranulocytosis
19. Adverse effects of clozapine
20. Clozapine-induced hypertension
21. Myocarditis and cardiomyopathy associated with clozapine
22. Myocarditis under therapy with clozapine
23. Cardiomyopathy associated with clozapine
24. Electrographic abnormalities in patients treated with clozapine
25. Supraventricular tachycardia in a patient receiving ECT, clozapine, and caffeine
26. Bilateral pulmonary embolism in a patient on clozapine therapy
27. Association of venous thromboembolism and clozapine
28. Pulmonary embolus possibly associated with clozapine treatment
29. Clozapine and pulmonary embolus
30. Clozapine therapy and pulmonary embolism
31. Mortality in current and former users of clozapine
32. Mortality risk and clozapine
33. Risperidone in the treatment of schizophrenia
34. Risperidone: Review of its pharmacology, and therapeutic use in scluzophrenia
35. Risperidone in the treatment of elderly patients with psychotic disorders
36. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: A parallel-group, double-blind comparative trial
37. The association between intravenous haloperidol and prolonged QT interval
38. Fatal cardiac event following initiation of risperidone therapy
39. Atrial ectopics with clozapine-risperidone combination
40. Tolerability and cardiovascular safety of risperidone
41. Olanzapine: Review of its pharmacology and indications in clinical practice
42. Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis
43. Long term side effects of novel antipsychotics
44. Seroquel (quetiapine): Preclinical and clinical findings of a new atypical antipsychotic
45. Quetiapine (Seroquel): A new "atypical" antipsychotic
46. Quetiapine: A new atypical antipsychotic
47. Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone
48. QT interval prolongation associated with quetiapine (seroquel) overdose
49. Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity
50. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4 week placebo-controlled trial
51. Ziprasidone 80 and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6 week placebo-controlled trial
52. Medical illness in patients with schizophrenia
53. The relationship between schizophrenia and IBS
54. The unhealthy lifestyle of people with schizophrenia
55. The association of medical comorbidity in schizophrenia with poor physical and mental health
56. Communication difficulty of patients with schizophrenia and physical illness
57. Physical diseases in schizophrenia and affective disorder
58. Excess mortality of schizophrenia: A meta-analysis
59. Medical disorders in schizophrenic patients
60. The effects of ketoconazole on ziprasidone pharmacokinetics-a placebo-controlled crossover study in healthy volunteers
61. Ziprasidone